Showing 7031-7040 of 9095 results for "".
- Bimekizumab Maintains Flare Control in HS Through 2 Yearshttps://practicaldermatology.com/news/bimekizumab-maintains-flare-control-in-hs-through-2-years/2484119/Bimekizumab provides sustained control of disease flares in patients with moderate-to-severe hidradenitis suppurativa (HS), with more than 83% of patients remaining flare-free over 96 weeks, according to interim results from the BE HEARD EXT study presented by Dr. H
- Deucravacitinib Provides Superior Real-World PsO Skin Clearance at 6 Monthshttps://practicaldermatology.com/news/deucravacitinib-provides-superior-real-world-pso-skin-clearance-at-6-months/2484117/Real-world data from the North American cohort of the RePhlect registry confirm that deucravacitinib provides significantly better skin clearance than apremilast at 6 months in adults with moderate-to-severe plaque psoriasis.
- Nemolizumab Shows Durable Patient-Reported Benefits at 100 Weeks in PNhttps://practicaldermatology.com/news/nemolizumab-shows-durable-patient-reported-benefits-at-100-weeks-in-pn/2484116/Long-term treatment with nemolizumab continues to deliver clinically meaningful improvements in itch, sleep, and quality of life for patients with prurigo nodularis (PN), according to interim results from the open-label extension (OLYMPIA-LTE) study presented by Dr
- Skin Cancer Champions Launches Integrated Public, Private Communityhttps://practicaldermatology.com/news/skin-cancer-champions-launches-integrated-public-private-community/2484106/The Skin Cancer Champions organization, led by dermatologists Emily Ruiz, MD, MPH, and Chrysalyne Schmults, MD, MSce, FAAD, announced the official launch of its integrated public and private community at skincancerchampions.org. The public platform expands the group’s reach by offering edu
- Study: Semaglutide Improves PASI Scoreshttps://practicaldermatology.com/news/study-semaglutide-improves-pasi-scores/2484098/Semaglutide may offer dual dermatologic and metabolic benefits in patients with psoriasis and obesity, even in the absence of diabetes, according to a 6-month prospective cohort study in Clinical and Experimental Dermatology.
- Dr. James Del Rosso Presents 'Medicine Chest' at Fall Clinicalhttps://practicaldermatology.com/news/dr-james-del-rossos-presents-medicine-chest-at-fall-clinical/2484096/A curated overview of skincare fundamentals, treatment pearls, and emerging data across acne, rosacea, hyperpigmentation, hidradenitis suppurativa (HS), and more was on display as James Q. Del Rosso, DO, presented “What’s New in the Medicine Chest” at the 2025 Fall Clinical Dermatology Conference
- CHE Talk at Fall Clinical Highlights Precision Therapieshttps://practicaldermatology.com/news/che-talk-at-fall-clinical-highlights-precision-therapies/2484094/With new FDA approvals, investigational therapies nearing the finish line, and a greater understanding of disease heterogeneity, chronic hand eczema (CHE) is increasingly viewed as a condition requiring individualized, mechanistically informed care, Alexandra Golant, MD, and Benjamin Ehst, MD, Ph
- Emerging Treatments for CLE Highlighted at Fall Clinicalhttps://practicaldermatology.com/news/emerging-treatments-for-cle-highlighted-at-fall-clinical/2484091/Cutaneous lupus erythematosus (CLE) patients often face long treatment timelines, drug toxicity, and misdiagnoses, but recent advances in mechanism-based agents mark a significant step forward, Lauren Graham, MD, PhD, and Alisa Femia, MD, said during a presentation at the 2025 Fall Clinical Derma
- Bullous Pemphigoid: The Time to Treat Is Now, Fall Clinical Speakers Sayhttps://practicaldermatology.com/news/bullous-pemphigoid-the-time-to-treat-is-now-fall-clinical-speakers-say/2484090/Earlier recognition of bullous pemphigoid (BP) is critical but safer, targeted treatment options are emerging for this aging and medically fragile patient population, according to a presentation from Donna Culton, MD, PhD, and Prince Adotama, MD, at the 2025 Fall Clinical Dermatology Conference.<
- New Deuruxolitinib Data Show It Meets 'The Need for Speed'https://practicaldermatology.com/news/new-deuruxolitinib-data-show-it-meets-the-need-for-speed/2484089/Deuruxolitinib resulted in significant hair regrowth starting at Week 8, continually improving through Week 24, and the 8-mg and 12-mg BID doses showed significant efficacy vs placebo across subgroups, according to new data presented at the 2025 Fall Clinical Dermatology Conference. Other